The application of virtual reality exposure versus relaxation training in music performance anxiety: a randomized controlled study.
Heart rate variability
Music performance anxiety
Progressive muscle relaxation
Virtual reality exposure therapy
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
received:
22
05
2023
accepted:
20
07
2023
medline:
3
8
2023
pubmed:
2
8
2023
entrez:
1
8
2023
Statut:
epublish
Résumé
Performance anxiety is the most frequently reported anxiety disorder among professional musicians. Typical symptoms are - on a physical level - the consequences of an increase in sympathetic tone with cardiac stress, such as acceleration of heartbeat, increase in blood pressure, increased respiratory rate and tremor up to nausea or flush reactions. These symptoms can cause emotional distress, a reduced musical and artistical performance up to an impaired functioning. While anxiety disorders are preferably treated using cognitive-behavioral therapy with exposure, this approach is rather difficult for treating music performance anxiety since the presence of a public or professional jury is required and not easily available. The use of virtual reality (VR) could therefore display an alternative. So far, no therapy studies on music performance anxiety applying virtual reality exposure therapy have investigated the therapy outcome including cardiovascular changes as outcome parameters. This mono-center, prospective, randomized and controlled clinical trial has a pre-post design with a follow-up period of 6 months. 46 professional and semi-professional musicians will be recruited and allocated randomly to an VR exposure group or a control group receiving progressive muscle relaxation training. Both groups will be treated over 4 single sessions. Music performance anxiety will be diagnosed based on a clinical interview using ICD-10 and DSM-5 criteria for specific phobia or social anxiety. A behavioral assessment test is conducted three times (pre, post, follow-up) in VR through an audition in a concert hall. Primary outcomes are the changes in music performance anxiety measured by the German Bühnenangstfragebogen and the cardiovascular reactivity reflected by heart rate variability (HRV). Secondary outcomes are changes in blood pressure, stress parameters such as cortisol in the blood and saliva, neuropeptides, and DNA-methylation. The trial investigates the effect of VR exposure in musicians with performance anxiety compared to a relaxation technique on anxiety symptoms and corresponding cardiovascular parameters. We expect a reduction of anxiety but also a consecutive improvement of HRV with cardiovascular protective effects. This study was registered on clinicaltrials.gov. (ClinicalTrials.gov Number: NCT05735860).
Sections du résumé
BACKGROUND
Performance anxiety is the most frequently reported anxiety disorder among professional musicians. Typical symptoms are - on a physical level - the consequences of an increase in sympathetic tone with cardiac stress, such as acceleration of heartbeat, increase in blood pressure, increased respiratory rate and tremor up to nausea or flush reactions. These symptoms can cause emotional distress, a reduced musical and artistical performance up to an impaired functioning. While anxiety disorders are preferably treated using cognitive-behavioral therapy with exposure, this approach is rather difficult for treating music performance anxiety since the presence of a public or professional jury is required and not easily available. The use of virtual reality (VR) could therefore display an alternative. So far, no therapy studies on music performance anxiety applying virtual reality exposure therapy have investigated the therapy outcome including cardiovascular changes as outcome parameters.
METHODS
This mono-center, prospective, randomized and controlled clinical trial has a pre-post design with a follow-up period of 6 months. 46 professional and semi-professional musicians will be recruited and allocated randomly to an VR exposure group or a control group receiving progressive muscle relaxation training. Both groups will be treated over 4 single sessions. Music performance anxiety will be diagnosed based on a clinical interview using ICD-10 and DSM-5 criteria for specific phobia or social anxiety. A behavioral assessment test is conducted three times (pre, post, follow-up) in VR through an audition in a concert hall. Primary outcomes are the changes in music performance anxiety measured by the German Bühnenangstfragebogen and the cardiovascular reactivity reflected by heart rate variability (HRV). Secondary outcomes are changes in blood pressure, stress parameters such as cortisol in the blood and saliva, neuropeptides, and DNA-methylation.
DISCUSSION
The trial investigates the effect of VR exposure in musicians with performance anxiety compared to a relaxation technique on anxiety symptoms and corresponding cardiovascular parameters. We expect a reduction of anxiety but also a consecutive improvement of HRV with cardiovascular protective effects.
TRIAL REGISTRATION
This study was registered on clinicaltrials.gov. (ClinicalTrials.gov Number: NCT05735860).
Identifiants
pubmed: 37528410
doi: 10.1186/s12888-023-05040-z
pii: 10.1186/s12888-023-05040-z
pmc: PMC10394851
doi:
Banques de données
ClinicalTrials.gov
['NCT05735860']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
555Informations de copyright
© 2023. The Author(s).
Références
Arch Gen Psychiatry. 2005 Feb;62(2):182-9
pubmed: 15699295
Depress Anxiety. 2019 Dec;36(12):1173-1181
pubmed: 31374578
Medicine (Baltimore). 2018 Dec;97(49):e13405
pubmed: 30544416
Front Psychol. 2019 Sep 10;10:1758
pubmed: 31551840
Behav Res Ther. 1998 Apr;36(4):455-70
pubmed: 9670605
Curr Opin Psychiatry. 2019 Jan;32(1):1-6
pubmed: 30480619
J Music Ther. 2008 Summer;45(2):165-91
pubmed: 18563972
Psychol Med. 2020 Nov;50(15):2487-2497
pubmed: 33070784
Circulation. 2000 Jan 4-11;101(1):8-10
pubmed: 10618296
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Psychother Psychosom Med Psychol. 2012 Feb;62(2):47-51
pubmed: 22203470
Front Psychol. 2020 May 29;11:1127
pubmed: 32547464
Behav Pharmacol. 2018 Apr;29(2 and 3-Spec Issue):140-151
pubmed: 29543648
Behav Res Ther. 2016 Feb;77:147-56
pubmed: 26752328
World Psychiatry. 2017 Jun;16(2):163-180
pubmed: 28498599
BMC Psychol. 2020 Aug 25;8(1):87
pubmed: 32843074
Front Psychol. 2014 Feb 04;5:25
pubmed: 24550856
Front Psychiatry. 2022 Apr 13;13:853733
pubmed: 35492712
J Anxiety Disord. 2019 Jan;61:27-36
pubmed: 30287083
Braz J Phys Ther. 2020 Mar - Apr;24(2):91-102
pubmed: 30852243
PLoS One. 2012;7(10):e46597
pubmed: 23056361
Am J Psychiatry. 1991 May;148(5):598-605
pubmed: 2018160
J R Soc Interface. 2013 Sep 25;10(89):20130719
pubmed: 24068177
Neurosci Biobehav Rev. 2022 Dec;143:104907
pubmed: 36243195
Cyberpsychol Behav. 2002 Dec;5(6):543-50
pubmed: 12556117
Front Psychol. 2021 Jan 06;11:618227
pubmed: 33488486
J Affect Disord. 1990 Mar;18(3):177-85
pubmed: 2139062
Psychol Med. 2019 Jan;49(2):200-211
pubmed: 30134999
Front Psychol. 2022 Mar 18;13:830230
pubmed: 35369260
J Affect Disord. 2021 Mar 15;283:139-146
pubmed: 33549878
J Occup Med Toxicol. 2008 Jul 25;3:16
pubmed: 18655716
Eur Arch Psychiatry Clin Neurosci. 2022 Jun;272(4):571-582
pubmed: 34609587
Transl Psychiatry. 2022 Feb 1;12(1):46
pubmed: 35105872
Front Psychol. 2020 Jun 16;11:1334
pubmed: 32612562
J Anxiety Disord. 2019 Jan;61:37-44
pubmed: 30580896
Med Probl Perform Art. 2015 Sep;30(3):169-77
pubmed: 26395619
Am J Psychiatry. 2001 Oct;158(10):1568-78
pubmed: 11578982
Front Public Health. 2017 Sep 28;5:258
pubmed: 29034226
Europace. 2009 Sep;11(9):1156-9
pubmed: 19633305
Med Probl Perform Art. 2019 Mar;34(1):53-60
pubmed: 30826822
Transl Psychiatry. 2019 Nov 21;9(1):314
pubmed: 31754096
Front Psychol. 2020 May 28;11:882
pubmed: 32547438
Psychol Med. 2008 Jan;38(1):15-28
pubmed: 17976249
PLoS One. 2017 Apr 24;12(4):e0176023
pubmed: 28437466
Curr Psychiatry Rep. 2017 Aug 15;19(10):67
pubmed: 28808909
Curr Heart Fail Rep. 2018 Apr;15(2):116-122
pubmed: 29520707
Trends Psychiatry Psychother. 2019 Oct-Dec;41(4):348-357
pubmed: 31967195
Med Probl Perform Art. 2015 Jun;30(2):100-5
pubmed: 26046615
Psychiatry Clin Neurosci. 2022 Jul;76(7):292-302
pubmed: 35340102
Psychopharmacology (Berl). 2020 Jun;237(6):1757-1767
pubmed: 32123973
Cell Mol Neurobiol. 2012 Jul;32(5):645-59
pubmed: 22271177
Front Psychol. 2021 Nov 25;12:725569
pubmed: 34899468
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Psychol Med. 2019 Oct;49(14):2287-2306
pubmed: 31474244
Clin Psychol Rev. 2020 Apr;77:101830
pubmed: 32163803
Front Psychol. 2021 Apr 23;12:538535
pubmed: 33967870
Psychoneuroendocrinology. 2013 Jun;38(6):729-43
pubmed: 23481259
Front Psychiatry. 2021 Jul 23;12:575094
pubmed: 34366904
J Music Ther. 2004 Spring;41(1):70-8
pubmed: 15157123
BJPsych Int. 2017 May 01;14(2):33-35
pubmed: 29093935
Prog Neuropsychopharmacol Biol Psychiatry. 2022 Mar 2;114:110478
pubmed: 34801611
Front Psychol. 2014 Jul 22;5:805
pubmed: 25101047
Front Hum Neurosci. 2018 Sep 25;12:372
pubmed: 30319376